Indian IT Firms Push Hard on Enterprise AI Adoption

Although domestic demand has been holding up following the recent GST rate reduction and income tax relief provided in the Budget, geopolitical developments have put pressure on equities markets. A bubble in the value of AI stocks is another hotly debated topic. Businessline discussed the AI factor and other matters with Nilesh Shah, MD of … Read more

Swiggy to Spend Majority of ₹10,000 Cr QIP on Quick-Commerce Expansion

Swiggy’s Rs 10,000 crore qualified institutional placement (QIP) will fund one of the company’s most aggressive development stages to date. Swiggy is a food and quick-commerce giant. According to the company’s most recent regulatory filing on December 9, over half of the proceeds—up to Rs 4,475 crore—will go toward expanding its quick-commerce infrastructure, despite the … Read more

Government Cuts IndiGo Flights by 10% to Stabilize Operations

IndiGo Q3 profit report and growth forecast update

In order to stabilize operations following a week of severe delays that left thousands of passengers stranded, the government has ordered a 10% reduction of IndiGo’s itineraries, according to Civil Aviation Minister Ram Mohan Naidu Kinjarapu’s announcement on Tuesday. The minister said in a statement posted on X that passengers all throughout the nation had … Read more

UPI Safety Tips for Families in 2025

The majority of consumers hardly give UPI a second thought before clicking “Pay” since it has become so ingrained in daily life. The speed is addicting, the ease is unparalleled, and the widespread use of QR codes almost eliminates the need for currency. However, this same easiness has made it easier for new types of … Read more

Zydus to Enter US Biosimilar Market with Keytruda Partner

In order to sell FYB206, a biosimilar of Merck’s popular cancer medication Keytruda (pembrolizumab), in the US and Canada, Zydus Lifesciences announced on Tuesday that it has signed an exclusive license and supply deal with Germany’s Formycon AG. The action is noteworthy because the US patent for Keytruda, one of the best-selling immunotherapies in the … Read more